Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Nov;122(11):2311-2315.e1.
doi: 10.1016/j.ophtha.2015.07.005. Epub 2015 Aug 15.

The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates

Brian L VanderBeek  1 , Sarah G Bonaffini  2 , Liyuan Ma  3
Affiliations
Comparative Study

The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates

Brian L VanderBeek et al. Ophthalmology. 2015 Nov.

Abstract

Purpose: To determine whether there is a difference in the risk of endophthalmitis after an intravitreal steroid injection compared with an anti-vascular endothelial growth factor (VEGF) agent injection.

Design: Retrospective cohort study.

Participants: A total of 75,249 beneficiaries in a large national US medical claims database representing 406 380 intravitreal injections.

Methods: Data were searched for all intravitreal injections (Current Procedural Terminology 67028) performed between 2003 and 2012. Cohorts were created on the basis of injections using anti-VEGF agents (bevacizumab, ranibizumab, aflibercept, and pegaptanib) and intraocular steroids (triamcinolone and dexamethasone). Endophthalmitis was defined as having a new endophthalmitis diagnosis (International Classification of Diseases 9th Revision 360.0x) and a "tap-and-inject" procedure (Current Procedural Terminology 67015, 67025), a vitrectomy (67036), or an intravitreal antibiotic injection on the same day, between 1 and 14 days post-injection. Exclusion occurred for any history of endophthalmitis, <6 months in the plan, or <1 month follow-up. The main outcome measure was the odds of endophthalmitis using logistic regression while controlling for injection-associated diagnosis, age, race, and gender.

Results: A total of 387,714 anti-VEGF injections and 18 666 steroid intravitreal injections were performed and followed by 73 (rate=0.019% or 1/5283 anti-VEGF injections) and 24 (rate=0.13% or 1/778 steroid injections) cases of endophthalmitis, respectively. After controlling for diagnosis, age, race, and gender, the odds ratio (OR) for endophthalmitis occurring was 6.92 (95% confidence interval, 3.54-13.52, P<0.001) times higher post-steroid injection compared with anti-VEGF injections.

Conclusions: The rate of endophthalmitis post-intravitreal steroid injection in a national cohort was 0.13% (1/778 injections). This rate conferred a significantly increased OR of 6.92 for endophthalmitis compared with anti-VEGF agents.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: No conflicting relationship exists for any author

Figures

Figure 1
Figure 1
Counts of injections after exclusion criteria:
See this image and copyright information in PMC

References

    1. Holekamp NM, Liu Y, Yeh WS, et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. American journal of ophthalmology. 2014;157:825–833. e1. - PubMed
    1. Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611–1621. - PMC - PubMed
    1. Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. American journal of ophthalmology. 2014 - PubMed
    1. Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29:875–912. - PubMed
    1. Francis JH, Marr BP, Brodie SE, et al. Tethered vitreous seeds following intravitreal melphalan for retinoblastoma. JAMA ophthalmology. 2014;132:1024–1025. - PubMed

Publication types

MeSH terms